查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1971122

RNAi药物递送市场分析及预测（至2035年）：依类型、产品类型、服务、技术、应用、最终用户、材料类型、製程、阶段划分

RNAi Drug Delivery Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Material Type, Process, Stage
出版日期: | 出版商: Global Insight Services | 英文 341 Pages | 商品交期: 3-5个工作天内

价格
简介目录

RNAi药物递送市场预计将从2024年的1,922亿美元成长到2034年的1,1,844亿美元，复合年增长率约为19.9%。 RNAi药物传递市场涵盖旨在有效递送RNA干扰疗法并增强基因静默能力的系统。这些技术在治疗遗传性疾病、癌症和病毒感染疾病至关重要。创新主要集中在提高递送效率、稳定性和标靶精准度。奈米技术的进步、RNAi研究投入的增加以及对个人化医疗解决方案日益增长的需求是推动该市场成长的主要因素。

RNAi药物递送市场正经历强劲成长，主要得益于治疗应用和创新递送技术的进步。脂质体药物递送系统细分市场成长最为迅猛，主要归功于其在提高RNAi稳定性和细胞摄取方面的有效性。脂质奈米颗粒凭藉其优异的递送能力和生物相容性，在该细分市场中尤其引人注目。聚合物体药物递送系统细分市场成长速度排名第二，其优势在于多功能性和标靶递送的潜力。树状树状聚合物因其能够提高药物溶解度和降低毒性，在该细分市场中备受关注。治疗应用细分市场也展现出良好的成长前景，其中肿瘤治疗领域占据主导地位，这主导归功于癌症患者数量的不断增长以及RNAi疗法靶向特定基因突变的潜力。遗传疾病细分市场紧随其后，反映出人们对RNAi在治疗罕见遗传疾病方面日益增长的兴趣。递送技术的创新和治疗适应症的拓展预计将推动未来市场的发展趋势。

市场区隔
类型 奈米颗粒、脂质体、高分子奈米微胞、外泌体、适配体、树状聚合物、胜肽
产品 siRNA、miRNA、shRNA、dsRNA
服务 客製化合成、分析服务、配方开发、规模化生产和法规支持
科技 化学偶联、脂质体、聚合物基递送、生物偶联递送
适应症 肿瘤科、心血管疾病科、神经系统疾病科、感染疾病、代谢疾病科、遗传性疾病科
最终用户 製药公司、生技公司、学术研究机构、受託研究机构
材料类型 脂质、聚合物、无机材料、胜肽
过程 包封、结合、络合
步 药物发现、临床前研究、临床研究、商业化

市场概况：

RNAi药物递送市场的特点是市场份额分布动态变化、定价策略创新以及新产品频繁推出。各公司不断完善产品系列，以满足日益增长的RNAi疗法需求。这种竞争环境孕育了创新文化，定价策略经过精心设计，力求在价格可负担性和盈利之间取得平衡。新型递送技术的引进是推动市场发展的关键因素，各公司竞相争取主导。 RNAi药物递送市场的竞争异常激烈，主要参与者不断相互参照，以保持竞争优势。监管的影响至关重要，尤其是在北美和欧洲，它塑造着市场动态和合规标准。严格的法规结构确保了药物的安全性和有效性，并影响打入市场策略。竞争环境的特征是策略联盟和收购，旨在增强技术能力和扩大市场覆盖范围。这种环境凸显了合规性和策略性定位对于永续成长的重要性。

主要趋势和驱动因素：

RNAi药物递送市场正经历强劲成长，主要得益于奈米技术和标靶递送系统的进步。这些创新提高了RNAi疗法的精准性和疗效，增强了治疗效果，同时减少了脱靶效应。慢性病和遗传性疾病的日益普遍推动了对基于RNAi的解决方案的需求，这些方案为传统治疗方法不足的领域提供了新的治疗途径。此外，个人化医疗的兴起，结合RNAi技术，正在促进根据每个人的基因谱制定个人化治疗方案。 RNAi疗法监管核准的加速进一步验证了其潜力，并支持了该领域的投资。生技公司与学术机构之间的合作正在推动研究，并引领RNAi应用领域的突破。此外，新兴市场不断扩大的医疗基础设施也为市场参与者提供了盈利的机会。专注于成本效益高的递送机制和可扩展生产流程的公司，将更有利于满足这一不断增长的需求。这些趋势和驱动因素预计将显着扩大RNAi药物递送市场，并变革医疗保健产业。

限制与挑战：

目前，RNAi药物递送市场面临许多重大限制与挑战。其中一个主要问题是递送系统的复杂性。开发高效安全的递送机制仍然是一项重大的科学挑战，阻碍了市场扩张。此外，监管障碍也加剧了这项挑战。 RNAi疗法的严格核准流程可能会延迟市场准入并增加成本。另一个挑战是RNAi药物的高生产成本。这些成本会限制其可近性并抑制投资。智慧财产权问题也构成重大障碍。专利纠纷与授权问题有可能扼杀产业内的创新与合作。此外，市场也面临其他治疗技术的竞争。其他治疗方法（例如CRISPR）的快速发展正在分散人们对RNAi的关注和资源。这些因素共同限制了RNAi药物递送解决方案的成长潜力和广泛应用。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 奈米颗粒
    • 脂质体
    • 聚合物胶束
    • 外泌体
    • 适体
    • 树状聚合物
    • 胜肽
  • 市场规模及预测：依产品划分
    • siRNA
    • 微型RNA
    • shRNA
    • dsRNA
  • 市场规模及预测：依服务划分
    • 客製合成
    • 分析服务
    • 配方开发
    • 扩大规模
    • 监管支持
  • 市场规模及预测：依技术划分
    • 化学键
    • 脂质奈米颗粒
    • 基于聚合物的递送
    • 生物复合物递送
  • 市场规模及预测：依应用领域划分
    • 肿瘤学
    • 心血管疾病
    • 神经系统疾病
    • 感染疾病
    • 代谢性疾病
    • 遗传性疾病
  • 市场规模及预测：依最终用户划分
    • 製药公司
    • 生技公司
    • 学术研究机构
    • 合约研究机构
  • 市场规模及预测：依材料类型划分
    • 脂质
    • 聚合物
    • 无机材料
    • 胜肽
  • 市场规模及预测：依製程划分
    • 封装技术
    • 加入
    • 错合的形成
  • 市场规模及预测：依发展阶段划分
    • 药物发现
    • 临床前阶段
    • 临床
    • 商业的

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Alnylam Pharmaceuticals
  • Arrowhead Pharmaceuticals
  • Silence Therapeutics
  • Dicerna Pharmaceuticals
  • Arcturus Therapeutics
  • Marina Biotech
  • Benitec Biopharma
  • RXi Pharmaceuticals
  • Bio-Path Holdings
  • Quark Pharmaceuticals
  • Sirnaomics
  • OliX Pharmaceuticals
  • Genevant Sciences
  • Regulus Therapeutics
  • Calando Pharmaceuticals

第九章：关于我们

简介目录
Product Code: GIS34222

RNAi Drug Delivery Market is anticipated to expand from $192.2 billion in 2024 to $1,184.4 billion by 2034, growing at a CAGR of approximately 19.9%. The RNAi Drug Delivery Market encompasses systems designed to deliver RNA interference therapeutics effectively within the body, enhancing gene silencing capabilities. These technologies are pivotal in treating genetic disorders, cancers, and viral infections. Innovations focus on improving delivery efficiency, stability, and targeting precision. The market is driven by advancements in nanotechnology, increased investment in RNAi research, and a growing demand for personalized medicine solutions.

The RNAi Drug Delivery Market is experiencing robust growth, propelled by advancements in therapeutic applications and innovative delivery technologies. The lipid-based delivery systems segment is the top performer, driven by its efficacy in enhancing RNAi stability and cellular uptake. Within this segment, lipid nanoparticles are particularly noteworthy for their superior delivery capabilities and biocompatibility. The polymer-based delivery systems segment is the second highest performing, offering versatility and potential for targeted delivery. In this segment, dendrimers are gaining attention for their ability to improve drug solubility and reduce toxicity. The therapeutic applications segment also shows promising growth, with oncology leading due to the increasing prevalence of cancer and the potential of RNAi therapies to target specific genetic mutations. The genetic disorders sub-segment follows closely, reflecting the growing interest in RNAi for treating rare genetic conditions. Innovation in delivery technologies and expanding therapeutic indications are set to drive the market's future trajectory.

Market Segmentation
TypeNanoparticles, Liposomes, Polymeric Micelles, Exosomes, Aptamers, Dendrimers, Peptides
ProductsiRNA, miRNA, shRNA, dsRNA
ServicesCustom Synthesis, Analytical Services, Formulation Development, Scale-Up, Regulatory Support
TechnologyChemical Conjugation, Lipid Nanoparticle, Polymer-Based Delivery, Bio-Conjugate Delivery
ApplicationOncology, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Metabolic Disorders, Genetic Disorders
End UserPharmaceutical Companies, Biotechnology Firms, Academic Research Institutes, Contract Research Organizations
Material TypeLipids, Polymers, Inorganic Materials, Peptides
ProcessEncapsulation, Conjugation, Complexation
StageDiscovery, Preclinical, Clinical, Commercial

Market Snapshot:

The RNAi Drug Delivery Market is characterized by a dynamic landscape of market share distribution, innovative pricing strategies, and frequent new product introductions. Companies are continuously enhancing their portfolios to cater to the rising demand for RNAi therapeutics. This competitive environment fosters a culture of innovation, where pricing strategies are carefully crafted to balance affordability with profitability. The introduction of novel delivery technologies is a significant driver, propelling the market forward as firms vie for leadership positions. Competition within the RNAi Drug Delivery Market is intense, with key players constantly benchmarking against each other to maintain competitive advantage. Regulatory influences, particularly in North America and Europe, are pivotal, shaping market dynamics and compliance standards. The stringent regulatory framework ensures safety and efficacy, impacting market entry strategies. The competitive landscape is marked by strategic alliances and acquisitions, aimed at enhancing technological capabilities and expanding market reach. This environment underscores the importance of regulatory navigation and strategic positioning for sustained growth.

Geographical Overview:

The RNAi drug delivery market is witnessing varied growth across regions, each presenting unique opportunities. North America leads due to advanced healthcare infrastructure and robust investments in biotechnology. The region's strong focus on research and development fosters innovation in RNAi technologies. Europe follows, with significant emphasis on personalized medicine and supportive regulatory frameworks driving market expansion. In Asia Pacific, the market is burgeoning, propelled by increasing healthcare expenditures and rapid technological advancements. Countries like China and India are emerging as key players, investing heavily in biopharmaceutical research. Latin America and the Middle East & Africa are nascent markets with growing potential. Latin America shows promise due to rising healthcare awareness and infrastructure development. Meanwhile, the Middle East & Africa are recognizing the potential of RNAi in addressing unmet medical needs, thus fueling market growth.

Key Trends and Drivers:

The RNAi Drug Delivery Market is experiencing robust growth, propelled by advancements in nanotechnology and targeted delivery systems. These innovations are enhancing the precision and efficacy of RNAi therapeutics, making treatments more effective and reducing off-target effects. The increasing prevalence of chronic diseases and genetic disorders is driving demand for RNAi-based solutions, as they offer novel therapeutic approaches where traditional methods fall short. Moreover, the rise of personalized medicine is aligning with RNAi technologies, fostering tailored treatment regimens that cater to individual genetic profiles. Regulatory approvals for RNAi therapies are accelerating, further legitimizing their potential and encouraging investment in this sector. Collaboration between biotech firms and academic institutions is spurring research, leading to breakthroughs in RNAi applications. Additionally, expanding healthcare infrastructure in emerging markets presents lucrative opportunities for market players. Companies focusing on cost-effective delivery mechanisms and scalable production processes are well-positioned to capture this growing demand. The RNAi Drug Delivery Market is poised for significant expansion as these trends and drivers converge, promising transformative impacts on healthcare.

Restraints and Challenges:

The RNAi Drug Delivery Market currently encounters several significant restraints and challenges. A primary issue is the complexity of delivery systems. Developing efficient and safe delivery mechanisms remains a formidable scientific hurdle, impeding market expansion. Furthermore, regulatory hurdles add to the challenge. The stringent approval processes for RNAi therapeutics can delay market entry and increase costs. Another challenge is the high production costs associated with RNAi drugs. These costs can limit accessibility and discourage investment. Intellectual property concerns also pose a significant barrier. Patent disputes and licensing issues can stifle innovation and collaboration within the industry. Additionally, the market faces competition from alternative therapeutic technologies. The rapid advancement of other modalities, such as CRISPR, diverts attention and resources away from RNAi. These factors collectively constrain the growth potential and broader adoption of RNAi drug delivery solutions.

Key Players:

Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Silence Therapeutics, Dicerna Pharmaceuticals, Arcturus Therapeutics, Marina Biotech, Benitec Biopharma, RXi Pharmaceuticals, Bio-Path Holdings, Quark Pharmaceuticals, Sirnaomics, OliX Pharmaceuticals, Genevant Sciences, Regulus Therapeutics, Calando Pharmaceuticals

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Material Type
  • 2.8 Key Market Highlights by Process
  • 2.9 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Nanoparticles
    • 4.1.2 Liposomes
    • 4.1.3 Polymeric Micelles
    • 4.1.4 Exosomes
    • 4.1.5 Aptamers
    • 4.1.6 Dendrimers
    • 4.1.7 Peptides
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 siRNA
    • 4.2.2 miRNA
    • 4.2.3 shRNA
    • 4.2.4 dsRNA
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Custom Synthesis
    • 4.3.2 Analytical Services
    • 4.3.3 Formulation Development
    • 4.3.4 Scale-Up
    • 4.3.5 Regulatory Support
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Chemical Conjugation
    • 4.4.2 Lipid Nanoparticle
    • 4.4.3 Polymer-Based Delivery
    • 4.4.4 Bio-Conjugate Delivery
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Cardiovascular Diseases
    • 4.5.3 Neurological Disorders
    • 4.5.4 Infectious Diseases
    • 4.5.5 Metabolic Disorders
    • 4.5.6 Genetic Disorders
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Pharmaceutical Companies
    • 4.6.2 Biotechnology Firms
    • 4.6.3 Academic Research Institutes
    • 4.6.4 Contract Research Organizations
  • 4.7 Market Size & Forecast by Material Type (2020-2035)
    • 4.7.1 Lipids
    • 4.7.2 Polymers
    • 4.7.3 Inorganic Materials
    • 4.7.4 Peptides
  • 4.8 Market Size & Forecast by Process (2020-2035)
    • 4.8.1 Encapsulation
    • 4.8.2 Conjugation
    • 4.8.3 Complexation
  • 4.9 Market Size & Forecast by Stage (2020-2035)
    • 4.9.1 Discovery
    • 4.9.2 Preclinical
    • 4.9.3 Clinical
    • 4.9.4 Commercial

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Material Type
      • 5.2.1.8 Process
      • 5.2.1.9 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Material Type
      • 5.2.2.8 Process
      • 5.2.2.9 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Material Type
      • 5.2.3.8 Process
      • 5.2.3.9 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Material Type
      • 5.3.1.8 Process
      • 5.3.1.9 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Material Type
      • 5.3.2.8 Process
      • 5.3.2.9 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Material Type
      • 5.3.3.8 Process
      • 5.3.3.9 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Material Type
      • 5.4.1.8 Process
      • 5.4.1.9 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Material Type
      • 5.4.2.8 Process
      • 5.4.2.9 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Material Type
      • 5.4.3.8 Process
      • 5.4.3.9 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Material Type
      • 5.4.4.8 Process
      • 5.4.4.9 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Material Type
      • 5.4.5.8 Process
      • 5.4.5.9 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Material Type
      • 5.4.6.8 Process
      • 5.4.6.9 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Material Type
      • 5.4.7.8 Process
      • 5.4.7.9 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Material Type
      • 5.5.1.8 Process
      • 5.5.1.9 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Material Type
      • 5.5.2.8 Process
      • 5.5.2.9 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Material Type
      • 5.5.3.8 Process
      • 5.5.3.9 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Material Type
      • 5.5.4.8 Process
      • 5.5.4.9 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Material Type
      • 5.5.5.8 Process
      • 5.5.5.9 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Material Type
      • 5.5.6.8 Process
      • 5.5.6.9 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Material Type
      • 5.6.1.8 Process
      • 5.6.1.9 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Material Type
      • 5.6.2.8 Process
      • 5.6.2.9 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Material Type
      • 5.6.3.8 Process
      • 5.6.3.9 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Material Type
      • 5.6.4.8 Process
      • 5.6.4.9 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Material Type
      • 5.6.5.8 Process
      • 5.6.5.9 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Alnylam Pharmaceuticals
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Arrowhead Pharmaceuticals
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Silence Therapeutics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Dicerna Pharmaceuticals
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Arcturus Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Marina Biotech
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Benitec Biopharma
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 RXi Pharmaceuticals
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Bio-Path Holdings
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Quark Pharmaceuticals
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Sirnaomics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 OliX Pharmaceuticals
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Genevant Sciences
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Regulus Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Calando Pharmaceuticals
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us